Is Mounjaro a Peptide — and Does the Label Actually Matter?

The biggest misconception: 'peptide' doesn't mean what most readers think

Search 'peptide weight loss' for five minutes and you will find a sprawling market of injections, powders and compounded vials, many sold without a prescription, most without clinical oversight. The reasonable assumption is that Mounjaro fits somewhere in that landscape. It does not. Tirzepatide is a peptide in the precise biochemical sense: a short chain of amino acids, synthesised in a laboratory to mimic the natural gut hormones GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). That is structurally and legally a different category from the unregulated 'research peptides' circulating online.

The MHRA licenses Mounjaro as a prescription-only medicine for weight management in adults; the NHS medicines guidance on tirzepatide sets out exactly what the medicine is indicated for and how it differs from other agents. If you have come across products described as 'peptide Mounjaro' or 'Mounjaro peptide alternative', they are not the same thing, and the MHRA has warned repeatedly about counterfeit and unlicensed injectable products entering the UK market. Worth checking: the GPhC pharmacy register lets you confirm in under a minute whether any online pharmacy dispensing these medicines is legitimately registered.

Tirzepatide's peptide structure was deliberately engineered to be stable enough for once-weekly dosing, fatty-acid conjugated to extend its half-life in the body. That is a long way from an off-the-shelf amino-acid compound.

How the dual-peptide mechanism translates to clinical results

Because tirzepatide activates two receptors rather than one, the physiological effects are broader than those of a GLP-1 agonist alone. GLP-1 stimulation slows gastric emptying and reduces appetite; GIP activation adds a complementary signal that appears to enhance the appetite-suppressing and metabolic effects of GLP-1. The combination is why the clinical evidence is striking. In SURMOUNT-1, a 72-week randomised trial involving 2,539 adults with obesity, participants on the 15 mg dose achieved an average body-weight reduction of around 20–21%, as published in the New England Journal of Medicine. NICE's appraisal of tirzepatide (TA1026) reviewed that evidence base before recommending the medicine for NHS use.

You can read a fuller breakdown of how tirzepatide's receptor activity compares with other GLP-1 medicines on our GLP-1 peptide and tirzepatide page. The short version: same drug class, different molecular target profile, meaningfully different average outcomes in head-to-head data.

Treatment starts at 2.5 mg (a dose designed to let your system adjust rather than to produce therapeutic weight loss immediately) and titrates upward under prescriber supervision. The prescriber decides the schedule; the Patient Information Leaflet covers the specifics of each step.

Peptide name, brand name, and what to look for when researching

Tirzepatide is the international non-proprietary name (the scientific peptide name) and Mounjaro is Eli Lilly's UK brand for it. The two are the same molecule. Some searches land on pages asking whether tirzepatide peptide is the same as Mounjaro, and the answer is straightforwardly yes: the peptide and the brand are one product, just named differently depending on context. In the US, Lilly markets tirzepatide for obesity under the name Zepbound, that brand does not exist in the UK, and US dosing or pricing information does not apply here.

For a closer look at the naming conventions and how the peptide designation maps to the licensed product, our page on Mounjaro's peptide name covers the terminology in detail. If you are thinking about treatment itself (costs, eligibility, what the private route looks like) our weight-loss treatment overview is a practical starting point.

One point worth stating plainly: tirzepatide's status as a peptide does not make it a supplement or a grey-area product. It is a regulated prescription medicine, and the clinical assessment that unlocks a prescription is the mechanism that keeps it safe. A real clinician reads your consultation (not software) and that review shapes whether and how treatment proceeds.

Eligibility and what comes next if tirzepatide is appropriate for you

The licensed eligibility criteria run from the SmPC: adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. BMI thresholds are adjusted downward for some ethnic backgrounds under UK clinical guidance. Whether those criteria apply to your specific situation is a clinical question, not a checkbox.

Our tirzepatide overview covers the full eligibility picture, including how NICE's NHS recommendations differ from the private licensed criteria. If you are already clear that you want to explore treatment, how to access Mounjaro through a regulated UK pharmacy explains the legal route and what to expect at each stage. The consultation at nume is free; it is reviewed the same day by a GPhC-registered prescriber from our clinical team, and if treatment is clinically appropriate, dispatch follows the same day for next-working-day delivery.

If you have broader questions about how GLP-1 and GIP peptide medicines compare or how tirzepatide fits within that class, the peptides and tirzepatide page goes deeper on the biochemistry.